Compile Data Set for Download or QSAR
Report error Found 333 Enz. Inhib. hit(s) with all data for entry = 229
TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 237552BDBM237552(rac-(3aR,5r,6aS)-5-(4- chlorobenzyl)-2-(2- hydroxy...)
Affinity DataIC50: 11.5nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 238867BDBM238867(rac-4-{2-[(3aR,5R,6aS)- 5-benzyl- octahydrocyclope...)
Affinity DataIC50: 11.7nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 238862BDBM238862(rac-4-{2-[(3aR,5S,6aS)- 5-benzyl- octahydrocyclope...)
Affinity DataIC50: 12.2nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 237388BDBM237388(rac-(3aR,5r,6aS)-2-(2- hydroxy-2-(4- hydroxyphenyl...)
Affinity DataIC50: 12.6nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 238861BDBM238861(rac-4-(2-((3aR,6aS)-5- benzylhexahydrocyclo- penta...)
Affinity DataIC50: 13.9nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 237683BDBM237683(rac-(3aR,5r,6aS)-5-(2- fluorobenzyl)-2-(2- hydroxy...)
Affinity DataIC50: 15.5nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 238865BDBM238865(rac-4-{2-[(3aR,5S,6aS)- 5-benzyl- octahydrocyclope...)
Affinity DataIC50: 16.8nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 235335BDBM235335(rac-(3aR,5r,6aS)-5- benzyl-2-(2-hydroxy-2- (4- hyd...)
Affinity DataIC50: 17.4nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 237322BDBM237322(rac-(3aR,5r,6aS)-5-(4- fluorobenzy)-2-(2- hydroxy-...)
Affinity DataIC50: 17.8nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 237551BDBM237551(rac-2-(2-(3-fluoro-4- hydroxyphenyl)-2- hydroxyeth...)
Affinity DataIC50: 19.3nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 238863BDBM238863(rac-4-{2-[(3aR,5R,6aS)- 5-benzyl- octahydrocyclope...)
Affinity DataIC50: 20.1nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 235341BDBM235341(US10052306, 143 | (3aR,5S,6aS)-5-benzyl-2- ((S)-2-...)
Affinity DataIC50: 20.4nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 235341BDBM235341(US10052306, 143 | (3aR,5S,6aS)-5-benzyl-2- ((S)-2-...)
Affinity DataIC50: 20.4nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 237325BDBM237325(rac-(3aR,5r,6aS)-2-(2-(3- fluoro-4-hydroxyphenyl)-...)
Affinity DataIC50: 22.1nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 237334BDBM237334((3aR,5R,6aS)-5-benzyl-2- ((R)-2-(3-fluoro-4- hydro...)
Affinity DataIC50: 22.3nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 238859BDBM238859(rac-6-(2-{5-benzyl- octahydrocyclopenta[c] pyrrol-...)
Affinity DataIC50: 22.4nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 235340BDBM235340(US10052306, 142 | (3aR,5R,6aS)-5-benzyl-2- ((R)-2-...)
Affinity DataIC50: 23.7nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 235340BDBM235340(US10052306, 142 | (3aR,5R,6aS)-5-benzyl-2- ((R)-2-...)
Affinity DataIC50: 23.7nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 237699BDBM237699(rac-5-(2,4- difluorobenzyl)-2-(2- hydroxy-2-(4- hy...)
Affinity DataIC50: 23.8nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 237709BDBM237709((3aR,5S,6aS)-5-(4- fluorobenzyl)-2-((S)-2- hydroxy...)
Affinity DataIC50: 24nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 235335BDBM235335(rac-(3aR,5r,6aS)-5- benzyl-2-(2-hydroxy-2- (4- hyd...)
Affinity DataIC50: 25.5nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 237544BDBM237544(rac-2-(2-hydroxy-2-(5- hydroxypyridin-2- yl)ethyl)...)
Affinity DataIC50: 25.7nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 235352BDBM235352(rac- (3aR,5r,6aS)-5- benzyl-2-(2-hydroxy-2- (5-hyd...)
Affinity DataIC50: 26.8nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 238874BDBM238874(rac-4-(2-((3aR,5r,6aS)-5- benzyl-5-fluoro- hexahyd...)
Affinity DataIC50: 26.9nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 235339BDBM235339(rac-(3aR,5r,6aS)-5-(4- fluorobenzyl)-2-(2- hydroxy...)
Affinity DataIC50: 27.1nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 237554BDBM237554(2-((3aR,5r,6aS)-5-(2- fluorobenzyl)-5- hydroxyhexa...)
Affinity DataIC50: 27.3nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 237379BDBM237379(rac-(3aR,5r,6aS)-2-(2- hydroxy-2-(4- hydroxyphenyl...)
Affinity DataIC50: 28.7nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 237687BDBM237687(rac-(3aR,5r,6aS)-5-(2,4- difluorobenzyl)-2-(2- hyd...)
Affinity DataIC50: 29.9nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 236487BDBM236487((3aR,5S,6aS)-5-benzyl-2- ((S)-2-(3-fluoro-4- hydro...)
Affinity DataIC50: 30.5nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 237707BDBM237707(rac-(3aR,5r,6aS)-5-(3,4- difluorobenzyl)-2-(2- hyd...)
Affinity DataIC50: 31.5nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 237331BDBM237331(rac-6-(2-((3aR,5r,6aS)-5- benzyl-5- methoxyhexahyd...)
Affinity DataIC50: 31.6nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 237710BDBM237710((3aR,5R,6aS)-5-(4- fluorobenzyl)-2-((R)-2- hydroxy...)
Affinity DataIC50: 31.7nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 237330BDBM237330(rac-4-(2-((3aR,5r,6aS)-5- benzyl-5- methoxyhexahyd...)
Affinity DataIC50: 32.4nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 237329BDBM237329(rac-4-(2-((3aR,5r,6aS)-5- benzyl-5- methoxyhexahyd...)
Affinity DataIC50: 32.4nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 237319BDBM237319((3aR,5R,6aS)-5-benzyl-2- ((R)-2-hydroxy-2-(5- hydr...)
Affinity DataIC50: 33.7nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 237369BDBM237369(rac-(3aR,5r,6aS)-2-(2- hydroxy-2-(4- hydroxyphenyl...)
Affinity DataIC50: 34.9nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 237545BDBM237545(2-[(3aR,5R,6aS)-5- hydroxy-5-{[4- (trifluoromethyl...)
Affinity DataIC50: 36nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 237383BDBM237383(rac-6-{2-[(3aR,5R,6aS)- 5-hydroxy-5-[(4- methoxyph...)
Affinity DataIC50: 36.3nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 238877BDBM238877(rac-4-(2-((3aR,5s,6aS)- 5-benzyl-5-fluoro- hexahyd...)
Affinity DataIC50: 36.4nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 237318BDBM237318((3aR,5S,6aS)-5-benzyl-2- ((S)-2-hydroxy-2-(5- hydr...)
Affinity DataIC50: 38.1nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 238864BDBM238864(2-[(3aR,5S,6aS)-5- benzyl- octahydrocyclopenta[c] ...)
Affinity DataIC50: 38.8nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 235387BDBM235387(rac-6-(2-((3aR,5r,6aS)-5- benzyl-5- hydroxyhexahyd...)
Affinity DataIC50: 40.2nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 237682BDBM237682(rac-5-(2-fluorobenzyl)-2- (2-hydroxy-2-(5- hydroxy...)
Affinity DataIC50: 40.9nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 238868BDBM238868(2-[(3aR,5S,6aS)-5- benzyl- octahydrocyclopenta[c] ...)
Affinity DataIC50: 41.2nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 237366BDBM237366(rac-(3aR,5R,6aS)-2-[2- hydroxy-2-(4- hydroxyphenyl...)
Affinity DataIC50: 41.5nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 237708BDBM237708(rac-(3aR,5r,6aS)-5-(4- fluoro-2-methylbenzyl)- 2-(...)
Affinity DataIC50: 42.5nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 238288BDBM238288(rac-(3aR,5R,6aS)-5- benzyl-2-[2-hydroxy-2- (4- hyd...)
Affinity DataIC50: 43nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 235338BDBM235338(2-((3aR,5r,6aS)-5-(4- fluorobenzyl)-5- hydroxyhexa...)
Affinity DataIC50: 43.2nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 237368BDBM237368(2-[(3aR,5R,6aS)-5- hydroxy-5-[(4- methoxyphenyl)me...)
Affinity DataIC50: 43.3nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Cadent Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 235334BDBM235334(2-((3aR,5r,6aS)-5-benzyl- 5- hydroxyhexahydrocyclo...)
Affinity DataIC50: 44.1nMAssay Description:To each well of the plate, 10 μL test compound, control (MK801) or HHnoCa buffer was added to a final concentration of 10 μM with a final c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2018
Entry Details
US Patent

Displayed 1 to 50 (of 333 total ) | Next | Last >>
Jump to: